{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:21:22Z","timestamp":1772166082976,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Both\u00a0human and veterinary cancer chemotherapy are undergoing a paradigm shift from a \u201cone size fits all\u201d approach to more\u00a0personalized, patient-oriented treatment strategies. Personalized chemotherapy is dependent on the identification and validation of biomarkers that can predict treatment outcome and\/or risk of toxicity. Many cytotoxic chemotherapy agents, including doxorubicin, base their mechanism of action by interaction with DNA and disruption of normal cellular processes. We developed a high-resolution\/accurate-mass liquid chromatography-mass spectrometry DNA screening approach for\u00a0monitoring doxorubicin-induced DNA modifications (adducts) in vitro and in vivo. We used, for the first time, a new strategy involving the use of isotope-labeled DNA, which greatly facilitates adduct discovery. The overall goal of this work was to identify doxorubicin-DNA adducts to be used as biomarkers to predict drug efficacy for use in veterinary oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We used our novel mass spectrometry approach to screen for adducts in purified DNA exposed to doxorubicin. This initial in vitro screening identified nine potential doxorubicin-DNA adduct masses, as well as an intense signal corresponding to DNA-intercalated doxorubicin. Two of the adduct masses, together with doxorubicin and its metabolite doxorubicinol, were subsequently detected in vivo in liver DNA extracted from mice exposed to doxorubicin. Finally, the presence of these adducts and analytes was explored in the DNA isolated from dogs undergoing treatment with doxorubicin. The previously identified nine DOX-DNA adducts were not detected in these preliminary three samples collected seven days post-treatment, however intercalated doxorubicin and doxorubicinol were detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This work sets the stage for future evaluation of  doxorubicin-DNA adducts and doxorubicin-related molecules as\u00a0candidate\u00a0biomarkers to personalize chemotherapy protocols for canine cancer patients. It demonstrates our ability to combine in one method the analysis of DNA adducts and DNA-intercalated doxorubicin and doxorubicinol. The last two analytes\u00a0interestingly, were persistent in samples from canine patients undergoing doxorubicin chemotherapy seven days after treatment. The presence of doxorubicin in all samples suggests a role for it as a promising biomarker for use in veterinary chemotherapy. Future studies will involve the analysis of more samples from canine cancer patients to elucidate optimal timepoints for monitoring intercalated\u00a0doxorubicin and\u00a0doxorubicin-DNA adducts and the correlation of these markers with therapy outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12917-021-03062-x","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T07:03:26Z","timestamp":1638860606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients"],"prefix":"10.1186","volume":"17","author":[{"given":"Kristine","family":"Walters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-9551","authenticated-orcid":false,"given":"Alessia","family":"Stornetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foster","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Villalta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Razzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beshay","family":"Zordoky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Bartolomucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Borgatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Balbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"issue":"7187","key":"3062_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature06915","volume":"452","author":"LJ van't Veer","year":"2008","unstructured":"van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452(7187):564\u201370.","journal-title":"Nature."},{"issue":"3","key":"3062_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","volume":"108","author":"R Fisher","year":"2013","unstructured":"Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479\u201385.","journal-title":"Br J Cancer"},{"issue":"10","key":"3062_CR3","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1172\/JCI60534","volume":"121","author":"K Polyak","year":"2011","unstructured":"Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786\u20138.","journal-title":"J Clin Invest"},{"issue":"3","key":"3062_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrd3651","volume":"11","author":"GJ Kelloff","year":"2012","unstructured":"Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012;11(3):201\u201314.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3062_CR5","first-page":"256","volume":"4","author":"N Goossens","year":"2015","unstructured":"Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4(3):256\u201369.","journal-title":"Transl Cancer Res"},{"issue":"16","key":"3062_CR6","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2007.15.5580","volume":"26","author":"MS Braun","year":"2008","unstructured":"Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26(16):2690\u20138.","journal-title":"J Clin Oncol"},{"key":"3062_CR7","doi-asserted-by":"publisher","first-page":"iv14","DOI":"10.1093\/annonc\/mdi902","volume":"16 Suppl 4","author":"A Paradiso","year":"2005","unstructured":"Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005;16 Suppl 4:iv14\u20139.","journal-title":"Ann Oncol"},{"key":"3062_CR8","doi-asserted-by":"crossref","unstructured":"van der Sijde F, Vietsch EE, Mustafa DAM, Besselink MG, Groot Koerkamp B, van Eijck CHJ. Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers (Basel). 2019;11(1):93.","DOI":"10.3390\/cancers11010093"},{"issue":"1","key":"3062_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.hoc.2016.08.006","volume":"31","author":"P Villalobos","year":"2017","unstructured":"Villalobos P, Wistuba II. Lung Cancer biomarkers. Hematol Oncol Clin North Am. 2017;31(1):13\u201329.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"3062_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-12-2982","volume":"19","author":"P Ascierto","year":"2013","unstructured":"Ascierto P, Kalos M, Schaer D, Callahan M, Wolchok J. Biomarkers for Immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res. 2013;19(5):1009\u201320.","journal-title":"Clin Cancer Res"},{"key":"3062_CR11","doi-asserted-by":"publisher","first-page":"117727191771523","DOI":"10.1177\/1177271917715236","volume":"12","author":"MJ Selleck","year":"2017","unstructured":"Selleck MJ, Senthil M, Wall NR. Making meaningful clinical use of biomarkers. Biomark Insights. 2017;12:1177271917715236.","journal-title":"Biomark Insights"},{"issue":"1","key":"3062_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1559-0275-10-13","volume":"10","author":"AK Fuzery","year":"2013","unstructured":"Fuzery AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics. 2013;10(1):13.","journal-title":"Clin Proteomics"},{"issue":"5","key":"3062_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00439-019-02020-w","volume":"138","author":"KL Mealey","year":"2019","unstructured":"Mealey KL, Martinez SE, Villarino NF, Court MH. Personalized medicine: going to the dogs? Hum Genet. 2019;138(5):467\u201381.","journal-title":"Hum Genet"},{"issue":"11","key":"3062_CR14","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","volume":"15","author":"CA London","year":"2009","unstructured":"London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009;15(11):3856\u201365.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"3062_CR15","first-page":"5729","volume":"9","author":"NK Pryer","year":"2003","unstructured":"Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res. 2003;9(15):5729\u201334.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3062_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1476-5829.2007.00147.x","volume":"6","author":"KR Vickery","year":"2008","unstructured":"Vickery KR, Wilson H, Vail DM, Thamm DH. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Vet Comp Oncol. 2008;6(2):111\u20139.","journal-title":"Vet Comp Oncol"},{"issue":"2","key":"3062_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/vco.12537","volume":"18","author":"DH Thamm","year":"2020","unstructured":"Thamm DH, Gustafson DL. Drug dose and drug choice: optimizing medical therapy for veterinary cancer. Vet Comp Oncol. 2020;18(2):143\u201351.","journal-title":"Vet Comp Oncol"},{"issue":"1","key":"3062_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jvim.12525","volume":"29","author":"KL Mealey","year":"2015","unstructured":"Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med. 2015;29(1):1\u20136.","journal-title":"J Vet Intern Med"},{"issue":"2","key":"3062_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/vco.12455","volume":"17","author":"LA Wittenburg","year":"2019","unstructured":"Wittenburg LA, Weishaar K, Ramirez D, Gustafson DL. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers. Vet Comp Oncol. 2019;17(2):147\u201354.","journal-title":"Vet Comp Oncol"},{"issue":"11","key":"3062_CR20","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2460\/ajvr.2004.65.1502","volume":"65","author":"DB Bailey","year":"2004","unstructured":"Bailey DB, Rassnick KM, Erb HN, Dykes NL, Hoopes PJ, Page RL. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors. Am J Vet Res. 2004;65(11):1502\u20137.","journal-title":"Am J Vet Res"},{"issue":"7","key":"3062_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"C Thorn","year":"2011","unstructured":"Thorn C, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein T, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440\u20136.","journal-title":"Pharmacogenet Genomics"},{"issue":"25","key":"3062_CR22","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","volume":"16","author":"C Carvalho","year":"2009","unstructured":"Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267\u201385.","journal-title":"Curr Med Chem"},{"issue":"2","key":"3062_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15216540500079093","volume":"57","author":"SM Cutts","year":"2005","unstructured":"Cutts SM, Nudelman A, Rephaeli A, Phillips DR. The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005;57(2):73\u201381.","journal-title":"IUBMB Life"},{"issue":"2","key":"3062_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","volume":"65","author":"O Tacar","year":"2013","unstructured":"Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157\u201370.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"3062_CR25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1021\/acs.chemrestox.6b00380","volume":"30","author":"A Stornetta","year":"2017","unstructured":"Stornetta A, Zimmermann M, Cimino GD, Henderson PT, Sturla SJ. DNA adducts from anticancer drugs as candidate predictive markers for precision medicine. Chem Res Toxicol. 2017;30(1):388\u2013409.","journal-title":"Chem Res Toxicol"},{"issue":"8","key":"3062_CR26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1021\/jm960835d","volume":"40","author":"DJ Taatjes","year":"1997","unstructured":"Taatjes DJ, Gaudiano G, Resing K, Koch TH. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem. 1997;40(8):1276\u201386.","journal-title":"J Med Chem"},{"issue":"12","key":"3062_CR27","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1093\/nar\/22.12.2296","volume":"22","author":"C Cullinane","year":"1994","unstructured":"Cullinane C, Cutts SM, van Rosmalen A, Phillips DR. Formation of adriamycin--DNA adducts in vitro. Nucleic Acids Res. 1994;22(12):2296\u2013303.","journal-title":"Nucleic Acids Res"},{"issue":"2 Suppl","key":"3062_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.taap.2004.12.020","volume":"207","author":"PB Farmer","year":"2005","unstructured":"Farmer PB, Brown K, Tompkins E, Emms VL, Jones DJ, Singh R, et al. DNA adducts: mass spectrometry methods and future prospects. Toxicol Appl Pharmacol. 2005;207(2 Suppl):293\u2013301.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1 Pt 1","key":"3062_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1006\/rtph.1996.0059","volume":"24","author":"ER Nestmann","year":"1996","unstructured":"Nestmann ER, Bryant DW, Carr CJ. Toxicological significance of DNA adducts: summary of discussions with an expert panel. Regul Toxicol Pharmacol. 1996;24(1 Pt 1):9\u201318.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"3","key":"3062_CR30","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1021\/ac403565m","volume":"86","author":"S Balbo","year":"2014","unstructured":"Balbo S, Hecht SS, Upadhyaya P, Villalta PW. Application of a high-resolution mass-spectrometry-based DNA adductomics approach for identification of DNA adducts in complex mixtures. Anal Chem. 2014;86(3):1744\u201352.","journal-title":"Anal Chem"},{"issue":"23","key":"3062_CR31","doi-asserted-by":"publisher","first-page":"11706","DOI":"10.1021\/acs.analchem.5b02759","volume":"87","author":"A Stornetta","year":"2015","unstructured":"Stornetta A, Villalta PW, Hecht SS, Sturla SJ, Balbo S. Screening for DNA alkylation mono and cross-linked adducts with a comprehensive LC-MS3 Adductomic approach. Anal Chem. 2015;87(23):11706\u201313.","journal-title":"Anal Chem"},{"key":"3062_CR32","doi-asserted-by":"crossref","unstructured":"Hu C, Chang Y, Cooke M, Chao M. DNA Crosslinkomics: A Tool for the Comprehensive Assessment of Interstrand Crosslinks Using High Resolution Mass Spectrometry. Anal Chem. 2019;91(23):15193\u2013203.","DOI":"10.1021\/acs.analchem.9b04068"},{"issue":"4","key":"3062_CR33","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/10715762.2011.653969","volume":"46","author":"M Dizdaroglu","year":"2012","unstructured":"Dizdaroglu M, Jaruga P. Mechanisms of free radical-induced damage to DNA. Free Radic Res. 2012;46(4):382\u2013419.","journal-title":"Free Radic Res"},{"issue":"5","key":"3062_CR34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/pbc.23254","volume":"58","author":"LA Johnson","year":"2012","unstructured":"Johnson LA, Malayappan B, Tretyakova N, Campbell C, MacMillan ML, Wagner JE, et al. Formation of cyclophosphamide specific DNA adducts in hematological diseases. Pediatr Blood Cancer. 2012;58(5):708\u201314.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"3062_CR35","first-page":"4465","volume":"9","author":"VL Souliotis","year":"2003","unstructured":"Souliotis VL, Dimopoulos MA, Sfikakis PP. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res. 2003;9(12):4465\u201374.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3062_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1172\/JCI112335","volume":"77","author":"E Reed","year":"1986","unstructured":"Reed E, Yuspa SH, Zwelling LA, Ozols RF, Poirier MC. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest. 1986;77(2):545\u201350.","journal-title":"J Clin Invest"},{"issue":"14","key":"3062_CR37","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1073\/pnas.84.14.5024","volume":"84","author":"E Reed","year":"1987","unstructured":"Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A. 1987;84(14):5024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3062_CR38","first-page":"229","volume":"2","author":"S Gupta-Burt","year":"1993","unstructured":"Gupta-Burt S, Shamkhani H, Reed E, Tarone R, Allegra C, Pai L, et al. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomark Prev. 1993;2(3):229\u201334.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5","key":"3062_CR39","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/bjc.2013.419","volume":"109","author":"I Nel","year":"2013","unstructured":"Nel I, Gauler TC, Eberhardt WE, Nickel AC, Schuler M, Thomale J, et al. Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment. Br J Cancer. 2013;109(5):1223\u20139.","journal-title":"Br J Cancer"},{"issue":"4","key":"3062_CR40","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/1535-7163.MCT-19-0133","volume":"19","author":"M Zimmermann","year":"2020","unstructured":"Zimmermann M, Li T, Semrad TJ, Wu CY, Yu A, Cimino G, et al. Oxaliplatin-DNA adducts as predictive biomarkers of FOLFOX response in colorectal Cancer: a potential treatment optimization strategy. Mol Cancer Ther. 2020;19(4):1070\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3062_CR41","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/ijc.25814","volume":"129","author":"PT Henderson","year":"2011","unstructured":"Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, et al. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011;129(6):1425\u201334.","journal-title":"Int J Cancer"},{"issue":"11","key":"3062_CR42","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1158\/1055-9965.EPI-08-0117","volume":"17","author":"S Balbo","year":"2008","unstructured":"Balbo S, Hashibe M, Gundy S, Brennan P, Canova C, Simonato L, et al. N2-ethyldeoxyguanosine as a potential biomarker for assessing effects of alcohol consumption on DNA. Cancer Epidemiol Biomark Prev. 2008;17(11):3026\u201332.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3062_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jpba.2015.11.035","volume":"119","author":"A Lucas","year":"2016","unstructured":"Lucas A, O'Neal S, Santos C, White T, Zamboni W. A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues. J Pharm Biomed Anal. 2016;119:122\u20139.","journal-title":"J Pharm Biomed Anal"},{"issue":"18","key":"3062_CR44","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1113\/JP280389","volume":"598","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Physiol. 2020;598(18):3793\u2013801.","journal-title":"J Physiol"},{"issue":"3","key":"3062_CR45","doi-asserted-by":"publisher","first-page":"H1098","DOI":"10.1152\/ajpheart.00832.2005","volume":"290","author":"X Yi","year":"2006","unstructured":"Yi X, Bekeredjian R, DeFilippis NJ, Siddiquee Z, Fernandez E, Shohet RV. Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2006;290(3):H1098\u2013102.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"18","key":"3062_CR46","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1161\/01.CIR.0000146889.46519.27","volume":"110","author":"N Nozaki","year":"2004","unstructured":"Nozaki N, Shishido T, Takeishi Y, Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation. 2004;110(18):2869\u201374.","journal-title":"Circulation."},{"issue":"1","key":"3062_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/sj.bjc.6690019","volume":"79","author":"J van Asperen","year":"1999","unstructured":"van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer. 1999;79(1):108\u201313.","journal-title":"Br J Cancer"},{"issue":"4","key":"3062_CR48","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1172\/JCI110328","volume":"68","author":"JH Doroshow","year":"1981","unstructured":"Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest. 1981;68(4):1053\u201364.","journal-title":"J Clin Invest"},{"issue":"10","key":"3062_CR49","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/cvr\/cvy064","volume":"114","author":"N Matsumura","year":"2018","unstructured":"Matsumura N, Zordoky BN, Robertson IM, Hamza SM, Parajuli N, Soltys CM, et al. Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes. Cardiovasc Res. 2018;114(10):1350\u20139.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"3062_CR50","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"M Oken","year":"1982","unstructured":"Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-03062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-021-03062-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-03062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T04:29:06Z","timestamp":1676003346000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-021-03062-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3062"],"URL":"https:\/\/doi.org\/10.1186\/s12917-021-03062-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-224712\/v1","asserted-by":"object"}]},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal procedures, both murine and canine, were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Minnesota and were carried out in accordance with relevant guidelines and regulations. Each owner provided written informed consent before the blood sample was taken from their dogs. Additionally, all animal studies, both murine and canine, were performed in compliance with the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}